ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

ASH HIGHLIGHTS 2024 ROUNDTABLE DISCUSSIONS
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Julie Bergeron

Icon Chair Speaker

Speaker

Dr. Lynn Savoie

Dr. Brett Houston

Studies / Trials Discussed

Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Studies/trials discussed:

Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
Tagged